Products for Research Use Only
RegisterLogin

Plogosertib

CAT: 0804-HY-147298-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-147298-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM) . Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers[1][2].
CAS Number
1137212-79-3
Product Name Alternative
CYC140
UNSPSC
12352005
Target
Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/plogosertib.html
Purity
98.59
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C2(CC2)CN(C3CCCC3)C4=NC(NC5=C(C=C(C=C5)C(N[C@@H]6CC[C@@H](N7CCN(CC7)C)CC6)=O)OC)=NC=C4N1C
Molecular Formula
C34H48N8O3
Molecular Weight
616.80
References & Citations
[1]Sylvie Moureau, et al. Abstract 4178: The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations. Cancer Res (2017) 77 (13_Supplement) : 4178.|[2]Moureau S, et al. Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia[J]. European Journal of Cancer, 2016, 1 (69) : S117. |[3]Susan Davis, et al. Treatment of proliferative diseases with pyrimidodiazepinones. Patent US20150320762A1.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PLK1; PLK2; PLK3

Alternative Products

CatalogName
MBS5813937Plogosertib

Popular Products